Liver Disease Landscape: Sorting through the drug development hype

Sponsored by: GlobalData

Focused on:

  • Non Alcoholic Steatohepatitis
  • Biliary Cholangitis
  • Liver
  • Disease

Date: 31 October

Days to go: 9

Time: 3PM London/11AM New York

Deciphering the liver disease treatment landscape

With the American Association for the Study of Liver Diseases (AASLD) conference approaching on 9th -13th November, GlobalData’s Senior Reporter Reynald Castaneda will discuss expert expectations for upcoming catalysts and trends in the liver disease field, as reported in past articles. We will be paying particular focus to three major indications—primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and hepatitis B virus (HBV)—and how the treatment landscapes are intertwined.

The PBC market presents large opportunities, with analysts predicting more than 120,000 Americans with PBC by 2020. Currently, first-line treatment is generic ursodeoxycholic acid (UDCA) with second-line treatment being Intercept Pharmaceuticals’ Ocaliva, which has an estimated peak worldwide sales of USD 394m by 2020 in PBC. Ocaliva is also expected to be one of the first approved drugs in NASH. We will showcase KOL’s thoughts on potential combination therapies in PBC, the comparisons in NASH and PBC markets as well as major upcoming catalysts in the field.

NASH is widely recognised as a blockbuster market, with analysts estimating the value to be upwards of USD 35bn. With no FDA-approved therapies for NASH, the race to market is tight, with a crowded field of more than 60 competitors with assets in clinical development. With various treatment targets and a large number of drugs in development, we will discuss some of the major high-impact events in NASH over the next year.

HBV is the most common cause of liver disease, with estimates that up to 2.2 million US citizens are chronically infected with the virus. This presentation will analyse therapies in development, including the potential for a functional cure.

In this webinar, Jennifer C. Smith-Parker, Editor, EMEA will moderate a discussion with Senior Reporter Reynald Castaneda on the relationships, trends and caveats in the treatment and diagnosis of PBC, NASH and HBV

Presented by

Reynald Castaneda,

Senior Reporter

Reynald Castaneda, prior to moving to London, was a journalist for healthcare newspaper New Zealand Doctor, covering primary care health politics and medical research. He has a BSc in Biological Sciences from the University of Auckland and a postgraduate diploma in journalism from AUT University. Prior to venturing into journalism, Reynald worked as a laboratory technician for Massey University’s Institute of Molecular Biosciences.
Coverage areas: Liver Diseases (NASH, HBV, HCV, PSC), Liver cancer, Gastric Cancer, Colon Cancer, Pancreatic Cancer, Melanoma

Jennifer C. Smith-Parker,

Editor, EMEA

Jennifer C. Smith-Parker joined the BioPharm Insight brand in October 2009, covering healthcare policy and regulatory news in Washington, DC. After developing excellent sources and fostering a reputation for producing in-depth analyses, scoops and trend pieces, she steadily rose in BPI’s ranks. She has attended conferences across the US and Europe and moderated BPI panels with industry leaders. Prior to BPI, she was associate news editor at FDA Week, covering FDA regulatory policy. She also worked at The Monitor newspaper in South Texas where she was awarded the Texas Medical Association’s Anson Jones journalism award for an article on breast cancer. Jennifer graduated from New York University with a BA with Honors in History and Journalism.

Key Learning Objectives

  • Gain insight into the treatment relationships, competitive pipelines and KOL expectations in PBC, NASH and HBV.
  • Identify which companies and therapeutics have potential roles in combination therapies to provide a functional cure in HBV.
  • Learn how KOLs see the future treatment paradigms in NASH, PBC and HBV and how the current development pipeline in these indications could influence their treatment.


  • Managers/Senior Managers/Associate Directors/Directors of Market Research
  • Business Insights
  • Market Intelligence
  • Strategic Insights
  • Forecasting
  • Pipeline Management
  • Competitive Strategy
  • Customer Insights
  • Heads of Research and Development
  • Heads of Product Planning and Marketing
  • Brand Managers
  • Market Access
  • Health Economics and Outcomes Research
  • Pharmaceutical Pricing
  • Pharmaceutical Licensing
  • Government and Public Affairs
  • Drug Development
  • Regulatory Affairs
  • Medical Affairs
  • Market Access Consultant
  • Fund Managers
  • Hedge Fund Managers
  • Contract Research Organisations
  • Clinical Research Manager